Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BORSI SEYED HAMID; RAJI HANIEH; Dargahi MalAmir Mehrdad; Nokhostin Forogh; Kargaran Afrooz

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Tehran University Medical Journal Year:2021 | Volume:79 | Issue:4 Page(s): 281-289

Download Full-Text

Persian Verion

View:

291

Download:

Cites:

Information Journal Paper

Title

Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial

Author(s)

Keywords

enoxaparinQ2

pulmonary thromboembolismQ1

rivaroxabanQ1

venous thromboembolismQ1

Abstract

Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. venous thromboembolism is a very common comorbidity in patients with cancer. Therefore, the aim of this study was to evaluate the efficacy and safety of the rivaroxaban compared with enoxaparin in patients with cancer and VTE. Methods: This randomized clinical trial was conducted on 50 patients with non-hematologic cancer and deep vein thrombosis (DVP) or pulmonary thromboembolism (PTE) enrolled into Imam Khomeini hospital, from November 2019 to March 2020 in Ahvaz. The participants randomly assigned in two treatment groups (25 patients in each group) of rivaroxaban (15 mg every 12 hours for the first three weeks and then orally at 20 mg daily) or enoxaparin (1 mg/kg by subcutaneous injection every 12 hours) and followed for 6 months to evaluate the efficacy, complications and safety (incidence of recurrent VTE, major bleeding and deaths) of these therapies in Ahvaz. Results: The three most common cancer diagnoses were breast (n=11, 22%), colon (n=10, 20%), and lung (n=7, 14%). Major bleeding at 6 months was only seen in one patient (4%) in the enoxaparin group and did not occur in the rivaroxaban group (P>0. 05). Minor bleeding occurred in 1 patient (4%) in the rivaroxaban group and did not occur in the enoxaparin group (P>0. 05). One patient in the enoxaparin group died because of fever and neutropenia. The prevalence of DVT and PTE in cancer patients was not significantly different based on patient age (P=0. 154), gender (P=0. 430), BMI (P=0. 490), underlying disease (P=0. 294), smoking (P=0. 955), type of cancer (P=0. 527), and metastatic cancer (P=0. 280). Conclusion: The results of this study suggest that the efficacy of rivaroxaban is not less than that of enoxaparin and therefore can be a potential option for patients with non-hematologic cancer and VTE. However, further randomized, controlled trials are needed to confirm these results.

Cites

No record.

References

No record.

Cite

APA: Copy

BORSI, SEYED HAMID, RAJI, HANIEH, Dargahi MalAmir, Mehrdad, Nokhostin, Forogh, & Kargaran, Afrooz. (2021). Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 79(4 ), 281-289. SID. https://sid.ir/paper/394095/en

Vancouver: Copy

BORSI SEYED HAMID, RAJI HANIEH, Dargahi MalAmir Mehrdad, Nokhostin Forogh, Kargaran Afrooz. Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2021;79(4 ):281-289. Available from: https://sid.ir/paper/394095/en

IEEE: Copy

SEYED HAMID BORSI, HANIEH RAJI, Mehrdad Dargahi MalAmir, Forogh Nokhostin, and Afrooz Kargaran, “Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 79, no. 4 , pp. 281–289, 2021, [Online]. Available: https://sid.ir/paper/394095/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops